Cargando…
Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis
OBJECTIVE: Although migraine is common, there are very few treatment options. Recently, lasmiditan, a specific 5-HT(1F) agonist, has gained approval as abortive therapy for migraine. This meta-analysis and trial sequential analysis (TSA) was performed to analyze efficacy and tolerability of lasmidit...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043817/ https://www.ncbi.nlm.nih.gov/pubmed/36722551 http://dx.doi.org/10.4103/ijp.ijp_901_21 |